These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 20203507)

  • 41. Postinfectious irritable bowel syndrome.
    Barbara G; Cremon C; Pallotti F; De Giorgio R; Stanghellini V; Corinaldesi R
    J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S95-7. PubMed ID: 19300138
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treating irritable bowel syndrome with probiotics: the evidence.
    Parkes GC; Sanderson JD; Whelan K
    Proc Nutr Soc; 2010 May; 69(2):187-94. PubMed ID: 20236566
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protease activated receptor 2: a new target for IBS treatment.
    Bueno L
    Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():95-102. PubMed ID: 18924448
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome.
    Zeng J; Li YQ; Zuo XL; Zhen YB; Yang J; Liu CH
    Aliment Pharmacol Ther; 2008 Oct; 28(8):994-1002. PubMed ID: 18671775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The spectrum of irritable bowel syndrome: A clinical review.
    Gilkin RJ
    Clin Ther; 2005 Nov; 27(11):1696-709. PubMed ID: 16368443
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostic and therapeutic strategies in the irritable bowel syndrome.
    Cremonini F; Talley NJ
    Minerva Med; 2004 Oct; 95(5):427-41. PubMed ID: 15467518
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome.
    Grover M; Herfarth H; Drossman DA
    Clin Gastroenterol Hepatol; 2009 Jan; 7(1):48-53. PubMed ID: 18848909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infection, inflammation, and the irritable bowel syndrome.
    Spiller R; Garsed K
    Dig Liver Dis; 2009 Dec; 41(12):844-9. PubMed ID: 19716778
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons.
    Balestra B; Vicini R; Cremon C; Zecchi L; Dothel G; Vasina V; De Giorgio R; Paccapelo A; Pastoris O; Stanghellini V; Corinaldesi R; De Ponti F; Tonini M; Barbara G
    Neurogastroenterol Motil; 2012 Dec; 24(12):1118-e570. PubMed ID: 22937879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Review article: probiotics and prebiotics in irritable bowel syndrome.
    Spiller R
    Aliment Pharmacol Ther; 2008 Aug; 28(4):385-96. PubMed ID: 18532993
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Functional gastrointestinal disorders and mast cells: implications for therapy.
    Barbara G; Stanghellini V; De Giorgio R; Corinaldesi R
    Neurogastroenterol Motil; 2006 Jan; 18(1):6-17. PubMed ID: 16371078
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuro-immune interactions in inflammatory bowel disease and irritable bowel syndrome: future therapeutic targets.
    Kraneveld AD; Rijnierse A; Nijkamp FP; Garssen J
    Eur J Pharmacol; 2008 May; 585(2-3):361-74. PubMed ID: 18417115
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis.
    Cremon C; Pallotti F; Bacchilega M; Stanghellini V; Corinaldesi R; Barbara G
    Expert Rev Gastroenterol Hepatol; 2008 Dec; 2(6):735-40. PubMed ID: 19090734
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Post-infectious irritable bowel syndrome. A review based on current evidence].
    Gómez-Escudero O; Schmulson-Wasserman MJ; Valdovinos-Díaz MA
    Rev Gastroenterol Mex; 2003; 68(1):55-61. PubMed ID: 12940101
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome.
    Camilleri M
    Expert Opin Pharmacother; 2013 Jun; 14(9):1151-60. PubMed ID: 23621801
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients.
    Kerckhoffs AP; Ter Linde JJ; Akkermans LM; Samsom M
    Neurogastroenterol Motil; 2008 Aug; 20(8):900-7. PubMed ID: 18363639
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
    Farthing MJ
    Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome.
    Frieling T; Meis K; Kolck UW; Homann J; Hülsdonk A; Haars U; Hertfelder HJ; Oldenburg J; Seidel H; Molderings GJ
    Z Gastroenterol; 2011 Feb; 49(2):191-4. PubMed ID: 21298604
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Irritable bowel syndrome and inflammatory bowel disease: Is there a connection?].
    Mearin F; Perelló A; Balboa A
    Gastroenterol Hepatol; 2009 May; 32(5):364-72. PubMed ID: 19442413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon?
    Cremon C; Carini G; De Giorgio R; Stanghellini V; Corinaldesi R; Barbara G
    Expert Rev Mol Diagn; 2010 May; 10(4):389-93. PubMed ID: 20465494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.